Britain’s drug regulator has authorized the Alzheimer’s drug Leqembi, saying that it’s the first medicine to show some impact in slowing progression of the neurodegenerative disease.

The first drug shown to slow Alzheimer’s hit the U.S. market over a year ago, but sales have lagged and diagnosis and treatment remain complicated.

Federal regulators are putting off a decision on Eli Lilly’s potential Alzheimer’s treatment with an unusual request to have an advisory committee examine the drug.

Some private insurers are balking at paying for the first drug fully approved to slow mental decline in Alzheimer’s patients.

These past few years are being called a major tipping point in Alzheimer's research. A second treatment has now been approved that targets the underlying cause of Alzheimer's, not just the symptoms.

New research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening.

U.S. officials have granted full approval to a closely watched Alzheimer’s drug for patients with early stages of the disease.

U.S. health advisers are backing the full approval of an Alzheimer's drug that received preliminary approval last year.

The first drug to show that it slows Alzheimer’s is on sale, but treatment for most patients is still several months away.

A new Alzheimer’s drug is hitting the market with experts voicing a lot of caution.

U.S. health officials have approved a new Alzheimer’s drug that modestly slows the brain-robbing disease.